BR0214319A - Uso de um agonista de receptor de canabinóide ou um sal farmaceuticamente aceitável ou um isÈmero ótico do mesmo, e, métodos para a inibição de relaxamentos transitórios do esfìncter esofágico inferior, o tratamento de doença do refluxo gastroesofágico, a prevenção do refluxo, o tratamento ou prevenção da regurgitação, doença do pulmão, asma e de laringite crÈnica e para controlar insuficiência de desenvolvimento - Google Patents

Uso de um agonista de receptor de canabinóide ou um sal farmaceuticamente aceitável ou um isÈmero ótico do mesmo, e, métodos para a inibição de relaxamentos transitórios do esfìncter esofágico inferior, o tratamento de doença do refluxo gastroesofágico, a prevenção do refluxo, o tratamento ou prevenção da regurgitação, doença do pulmão, asma e de laringite crÈnica e para controlar insuficiência de desenvolvimento

Info

Publication number
BR0214319A
BR0214319A BR0214319-4A BR0214319A BR0214319A BR 0214319 A BR0214319 A BR 0214319A BR 0214319 A BR0214319 A BR 0214319A BR 0214319 A BR0214319 A BR 0214319A
Authority
BR
Brazil
Prior art keywords
treatment
prevention
regurgitation
asthma
inhibition
Prior art date
Application number
BR0214319-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Anders Lehmann
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0214319A publication Critical patent/BR0214319A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BR0214319-4A 2001-11-23 2002-11-20 Uso de um agonista de receptor de canabinóide ou um sal farmaceuticamente aceitável ou um isÈmero ótico do mesmo, e, métodos para a inibição de relaxamentos transitórios do esfìncter esofágico inferior, o tratamento de doença do refluxo gastroesofágico, a prevenção do refluxo, o tratamento ou prevenção da regurgitação, doença do pulmão, asma e de laringite crÈnica e para controlar insuficiência de desenvolvimento BR0214319A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0103936 2001-11-23
PCT/SE2002/002108 WO2003043619A1 (en) 2001-11-23 2002-11-20 New use for the treatment of gastroesophageal reflux disease

Publications (1)

Publication Number Publication Date
BR0214319A true BR0214319A (pt) 2004-11-03

Family

ID=20286096

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0214319-4A BR0214319A (pt) 2001-11-23 2002-11-20 Uso de um agonista de receptor de canabinóide ou um sal farmaceuticamente aceitável ou um isÈmero ótico do mesmo, e, métodos para a inibição de relaxamentos transitórios do esfìncter esofágico inferior, o tratamento de doença do refluxo gastroesofágico, a prevenção do refluxo, o tratamento ou prevenção da regurgitação, doença do pulmão, asma e de laringite crÈnica e para controlar insuficiência de desenvolvimento

Country Status (20)

Country Link
US (1) US7358245B2 (https=)
EP (1) EP1453497A1 (https=)
JP (1) JP2005511632A (https=)
KR (1) KR20050044582A (https=)
CN (1) CN1610542A (https=)
AR (1) AR037299A1 (https=)
AU (1) AU2002353700A1 (https=)
BR (1) BR0214319A (https=)
CA (1) CA2466916A1 (https=)
HU (1) HUP0402080A3 (https=)
IL (1) IL161748A0 (https=)
IS (1) IS7272A (https=)
MX (1) MXPA04004774A (https=)
NO (1) NO20042613L (https=)
NZ (1) NZ532844A (https=)
PL (1) PL369402A1 (https=)
RU (1) RU2280443C2 (https=)
TW (1) TW200407110A (https=)
WO (1) WO2003043619A1 (https=)
ZA (1) ZA200403785B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06004434A (es) * 2003-10-24 2006-06-20 Solvay Pharm Gmbh Usos medicos novedosos de compuestos que muestran actividad antagonista cb1 y tratamiento de combinacion que involucra tales compuestos.
WO2005060971A1 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of reflux-related diseases
SE0303490D0 (sv) * 2003-12-19 2003-12-19 Astrazeneca Ab New use V
JP2008517976A (ja) 2004-10-25 2008-05-29 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ１カンナビノイド受容体拮抗薬及びカリウムチャンネルオープナーから成る、真性糖尿病１型、肥満及び関連症状の治療用の医薬組成物
EP1827393A4 (en) * 2004-12-09 2012-04-18 Insys Therapeutics Inc AT ROOM TEMPERATURE, STABLE DRONABINOL FORMULATIONS
WO2008019146A2 (en) * 2006-08-04 2008-02-14 Insys Therapeutics Inc. Aqueous dronabinol formulations
JP2010535774A (ja) * 2007-08-06 2010-11-25 インシス セラピューティクス インコーポレイテッド 経口カンナビノイド液体製剤および治療方法
JP2010540618A (ja) * 2007-10-02 2010-12-24 アリエル−ユニバーシティー リサーチ アンド デベロップメント カンパニー リミテッド 幼児の成長および発達を増大するための内在性カンナビノイド
US20090208588A1 (en) * 2008-02-19 2009-08-20 Roger Wayne Brown GERD carbohydrate compositions
CN103588672A (zh) * 2013-10-28 2014-02-19 史克勇 一种治疗癌性疼痛的药物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2735774B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
WO1997029079A1 (en) * 1996-02-06 1997-08-14 Japan Tobacco Inc. Novel compounds and pharmaceutical use thereof
US5939429A (en) * 1997-09-30 1999-08-17 Virginia Commonwealth University Cardiovascular uses of cannabinoid compounds
CA2340445A1 (en) 1998-05-04 1999-11-11 The University Of Connecticut Novel analgesic and immunomodulatory cannabinoids
US6348498B1 (en) 1998-05-29 2002-02-19 Neurosciences Research Foundation, Inc. Control of pain with endogenous cannabinoids
GB9923738D0 (en) 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
IL132661A (en) * 1999-10-31 2008-11-26 Raphael Mechoulam Agonists specific for peripheral cannabinoid receptors
SE9904507D0 (sv) * 1999-12-09 1999-12-09 Astra Ab New compounds
ES2291323T3 (es) * 2000-06-15 2008-03-01 Schering Corporation Antagonistas de receptores de trombina.
AUPR118000A0 (en) * 2000-11-02 2000-11-23 Amrad Operations Pty. Limited Therapeutic molecules and methods
FR2816938B1 (fr) 2000-11-22 2003-01-03 Sanofi Synthelabo Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant
US20020077322A1 (en) * 2000-12-15 2002-06-20 Ayoub George S. Protection of neurons against glutamate-induced damage in glaucoma and other conditions

Also Published As

Publication number Publication date
HUP0402080A2 (hu) 2005-02-28
IL161748A0 (en) 2005-11-20
IS7272A (is) 2004-05-19
AR037299A1 (es) 2004-11-03
MXPA04004774A (es) 2004-07-30
HUP0402080A3 (en) 2008-03-28
US7358245B2 (en) 2008-04-15
NZ532844A (en) 2005-12-23
RU2280443C2 (ru) 2006-07-27
WO2003043619A1 (en) 2003-05-30
AU2002353700A1 (en) 2003-06-10
RU2004114843A (ru) 2005-05-27
ZA200403785B (en) 2005-05-19
KR20050044582A (ko) 2005-05-12
NO20042613L (no) 2004-08-13
TW200407110A (en) 2004-05-16
JP2005511632A (ja) 2005-04-28
US20040266861A1 (en) 2004-12-30
EP1453497A1 (en) 2004-09-08
PL369402A1 (en) 2005-04-18
CN1610542A (zh) 2005-04-27
CA2466916A1 (en) 2003-05-30
WO2003043619A8 (en) 2005-03-17

Similar Documents

Publication Publication Date Title
BR0214319A (pt) Uso de um agonista de receptor de canabinóide ou um sal farmaceuticamente aceitável ou um isÈmero ótico do mesmo, e, métodos para a inibição de relaxamentos transitórios do esfìncter esofágico inferior, o tratamento de doença do refluxo gastroesofágico, a prevenção do refluxo, o tratamento ou prevenção da regurgitação, doença do pulmão, asma e de laringite crÈnica e para controlar insuficiência de desenvolvimento
BR0314603A (pt) Uso de inibidores da sìntese de citoquina para o tratamento de distúrbios de olhos secos
DE60124524D1 (de) Optisches reduktionssystem mit kontrolle der belichtungspolarisation
EP1996122A4 (en) MOMENT-INDUCED ARTHROPLASTY TOTAL PROSTHESIS
DE60124863D1 (de) Gegen menschliche interleukin-1-beta gerichtete rekombinante antikörper
CY2014019I2 (el) Παραγωγα φαιναιθανολαμινης για θεραπεια ασθενειων του αναπνευστικου
FR2930160B1 (fr) Ensemble de protection d'aiguille.
UY28958A1 (es) Nuevos derivados de piridazin-3(2h)-ona
IL224393B (en) Compositions for treatment of huntington's disease
DE60114044D1 (de) Herstellung beschichteter medizinischer geräte mittels laserablation
ATE506360T1 (de) Neue benzimidazolderivate
PT1309324E (pt) Derivados de anticonvulsivos uteis para o tratamento e prevencao do desenvolvimento de diabetes mellitus do tipo ii e da sindroma x
EP1965823A4 (en) METHOD FOR THE ADMINISTRATION OF HYPOGLYKEMIC AGENTS
EP2074614A4 (en) CONNECTING ELEMENT FOR THE NECK OF A MUSICAL INSTRUMENT
EP2171592A4 (en) PARALLELIZATION OF SEQUENCIAL FRAMEWORK CONDITIONS USING TRANSACTIONS
EP2054243A4 (en) DRYING PREVENTING SLIDER WRITING DEVICE
EP1599217A4 (en) PROCESS FOR PREVENTING VIRUS REPLICATION IN VIVO
CL2007003643A1 (es) Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas.
DE60215256D1 (de) Verwendung eines Ferulasäurederivats als Vorbeugungs- oder Heilmittel gegen Hypertonie
EP1590624A4 (en) INTERFEROMETERAUSRICHTUNG
EP1793867A4 (en) ILLUSTRATION OF TRANSGENEXPRESSIONREPORTERS
PE20020547A1 (es) Uso de la tolterodina en tratamientos del asma
EP1924684A4 (en) Transition state structure of 5'-methylthioadenosine/s-adenosylhomocysteine nucleosidases
AR059789A1 (es) "dominios kunitz quimericos y su uso "
FR2874855B1 (fr) Instrument d'ecriture

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE A 8.6, DA RPI 2108 DE 31/05/2011.